Literature DB >> 28716321

Contemporary Evaluation and Treatment of Poststroke Lower Urinary Tract Dysfunction.

Zachary Panfili1, Meredith Metcalf1, Tomas L Griebling2.   

Abstract

Stroke is an extremely common clinical entity, and poststroke incontinence is a major cause of morbidity for stroke survivors. Although patients can experience a wide variety of lower urinary tract symptoms, detrusor overactivity is among the most common clinical findings following stroke. All forms of lower urinary tract symptoms can negatively impact physical and psychosocial function for affected patients and their caregivers and loved ones. Careful evaluation is critical for successful management. Treatment is tailored to the goals and needs of each individual patient. Improvements in continence status can help to enhance overall and health-related quality of life.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Geriatrics; Lower urinary tract symptoms (LUTS); Overactive bladder (OAB); Stroke; Underactive bladder (UAB); Urinary incontinence

Mesh:

Year:  2017        PMID: 28716321     DOI: 10.1016/j.ucl.2017.04.007

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  3 in total

Review 1.  Lower urinary tract dysfunction in common neurological diseases.

Authors:  Mohamad Moussa; Athanasios Papatsoris; Mohamed Abou Chakra; Yousef Fares; Athanasios Dellis
Journal:  Turk J Urol       Date:  2020-04-30

2.  Transcutaneous Electrical Spinal Cord Neuromodulator (TESCoN) Improves Symptoms of Overactive Bladder.

Authors:  Evgeniy Kreydin; Hui Zhong; Kyle Latack; Shirley Ye; V Reggie Edgerton; Parag Gad
Journal:  Front Syst Neurosci       Date:  2020-02-06

3.  Effects of tibial and parasacral nerve electrostimulation techniques on women with poststroke overactive bladder: study protocol for a randomized controlled trial.

Authors:  Thais Alves Candido; Bruna Miranda Ribeiro; Cristiane Rodrigues Cardoso de Araújo; Rogério de Melo Costa Pinto; Ana Paula Magalhães Resende; Vanessa Santos Pereira-Baldon
Journal:  Trials       Date:  2020-11-19       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.